Skip to content
November 27, 2022

Equity.Guru

Investment information for the new generation

Search Results for: XPHY.C

Xphyto Therapeutics (XPHY.C) provided a market and product update on its Rotigotine transdermal (TDS) patch, originally developed by their German subsidiary, Vektor Pharma TF GmbH. If you’re interested in…
XPhyto Therapeutics (XPHY.C) announced today that it has successfully launched its 25-minute COVID-19 polymerase chain reaction COVID-ID Lab. “The straightforward testing protocol, without prior RNA extraction as part of…
XPhyto Therapeutics (XPHY.C), with its partner and acquisition target, 3a-diagnostics GmbH announced today that it has successfully registered its first biosensor test in oral inflammation with the German authorities….
On July 28, 2021 Xphyto Therapeutics (XPHY.C) announced that its acquisition target, 3a-diagnostics GmbH, has identified the first saliva-activated in-mouth biosensor candidates for the detection of a COVID-19 infection….
Hugh Rogers, Xphyto Therapeutics (XPHY.C) CEO and director, explains the company’s innovative three-pronged business plan involving diagnostics and drug delivery as well as the company’s potential and longevity in…
XPhyto Therapeutics (XPHY.C) announced today that it has signed a definitive agreement for the acquisition of 3a-Diagnostics GmhB, Frickenhausen, Germany, XPhyto’s exclusive diagnostic development partner. Read full article here:…
XPhyto Therapeutics (XPHY.C) announced today that it has signed a definitive agreement for the acquisition of 3a-Diagnostics GmhB, Frickenhausen, Germany, XPhyto’s exclusive diagnostic development partner.     “We have…
XPhyto Therapeutics (XPHY.C) announced today that it has signed a master supply agreement with Beovita GmhB and Tackleberries GmbH, two German diagnostics, testing and medical logistics companies. Cumulatively, both…
XPhyto Therapeutics (XPHY.C) announced today that it has signed a master supply agreement with Beovita GmhB and Tackleberries GmbH, two German diagnostics, testing and medical logistics companies. Cumulatively, both…
XPhyto Therapeutics (XPHY.C) announced today that its Good Manufacturing Practice (GMP) mescaline synthesis program is on schedule with the completion of initial production batches. Read full article here: https://equity.guru/2021/06/08/xphyto-therapeutics-xhpy-c-provides-progress-report-on-mescaline-program/…